Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences
BTIG Virtual Biotechnology Conference2020. Eiger will participate in a fireside chat with live webcast on Monday, August 10, 12:30-12:55 PM ET. Eiger will also host one-on-one meetings.
Wedbush PacGrow Virtual Healthcare Conference. Eiger will present a corporate update with live webcast on Wednesday, August 12, 3:30-4:00 PM ET. Eiger will also host one-on-one meetings.
Live webcasts of the BTIG fireside chat and Wedbush presentation will be available on the
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs, for which no approved therapies exist.
Eiger's lead programs target Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis. Eiger is developing two complementary treatments for HDV. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.
Eiger has filed an NDA and MAA for lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. FDA PDUFA date is
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors and Media:
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2020-investor-conferences-301104509.html